Hims & Hers HealthHIMS
HIMS
About: Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Employees: 1,637
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
225% more first-time investments, than exits
New positions opened: 130 | Existing positions closed: 40
55% more capital invested
Capital invested by funds: $2.56B [Q3] → $3.97B (+$1.41B) [Q4]
27% more funds holding
Funds holding: 304 [Q3] → 387 (+83) [Q4]
25% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 104
11.35% more ownership
Funds ownership: 66.8% [Q3] → 78.16% (+11.35%) [Q4]
0% more call options, than puts
Call options by funds: $384M | Put options by funds: $383M
25% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$22
27%
downside
Avg. target
$43
43%
upside
High target
$68
125%
upside
9 analyst ratings
3 positive
33%
4 neutral
44%
2 negative
22%
B of A Securities Allen Lutz 60% 1-year accuracy 9 / 15 met price target | 27%downside $22 | Underperform Maintained | 18 Mar 2025 |
Citigroup Daniel Grosslight 39% 1-year accuracy 9 / 23 met price target | 10%downside $27 | Sell Reiterated | 6 Mar 2025 |
Truist Securities Jailendra Singh 40% 1-year accuracy 14 / 35 met price target | 29%upside $39 | Hold Maintained | 26 Feb 2025 |
Leerink Partners Michael Cherny 68% 1-year accuracy 19 / 28 met price target | 33%upside $40 | Market Perform Maintained | 25 Feb 2025 |
Piper Sandler Korinne Wolfmeyer 28% 1-year accuracy 13 / 47 met price target | 16%upside $35 | Neutral Maintained | 25 Feb 2025 |
Financial journalist opinion
Based on 40 articles about HIMS published over the past 30 days
Negative
The Motley Fool
6 hours ago
Is Hims & Hers Health Stock a Smart Buy After Plunging More Than 50%?
What goes up can come down. Investors who jumped on the Hims & Hers Health (HIMS -4.12%) bandwagon have experienced this pain first-hand.
Negative
Invezz
1 day ago
Here's why Hims & Hers stock price has crashed: buy the dip?
Hims & Hers stock price has imploded this year, erasing some of the gains made in 2024 when it became one of the top-performing companies in the US. HIMS has crashed to $33.35, down by over 54% from its highest point this year.
Positive
Seeking Alpha
2 days ago
Hims & Hers Health: Reaching Escape Velocity Goes Unnoticed By The Market
I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS' stock drop, in my view. 2025 revenue guidance of $2.29-$2.39 billion and a 3.6x multiple on its $8.3 billion market cap suggest undervaluation. HIMS' PEG ratio of ~1 (P/E of 58 ÷ 56% growth) signals undervaluation for a high-growth company, typically seen in mature firms, not one scaling at 50%+ with 85% customer.
Neutral
Zacks Investment Research
2 days ago
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) reachead $37.04 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
Positive
Zacks Investment Research
3 days ago
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Positive
Seeking Alpha
3 days ago
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and women's health, dermatology, and mental health, along with its personalized healthcare solutions, supports long-term growth potential. Strong financial performance with a 69% revenue increase in 2024, a growing subscriber base, and improved marketing efficiency highlight H&H's disciplined growth strategy.
Neutral
The Motley Fool
3 days ago
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Hims & Hers Health Popped
Novo Nordisk (NVO -2.06%) stock slipped 1.7% through 12:10 a.m. ET Monday on a pair of news items with which investors seem less than thrilled:
Positive
Zacks Investment Research
4 days ago
Hims & Hers Health (HIMS) Moves 5.7% Higher: Will This Strength Last?
Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Positive
Seeking Alpha
1 week ago
Hims & Hers Health: Developing A Better Understanding
Hims & Hers Health has become one of the most popular growth stocks in the market today. After sharing with my readers a bullish perspective on the stock at ~$6/share in 2023, I'm back to provide a unique perspective that sheds light on what the platform does. In short, I like to call Hims an "AI-orchestrated general physician at national scale," and I'll walk us through what that means today.
Positive
Seeking Alpha
1 week ago
Jumping Into The FDA Gamble: Initiating Hims & Hers With A Buy
Hims & Hers Health, Inc. stock surged to $68, and the subsequent 50% crash is the talk of the town. I'm eyeing it as a favorable high-risk, high-reward play. HIMS stock plummeted after the FDA halted approval of its top-selling GLP-1 weight loss drug, which is priced at $165 and offers the same as Ozempic, priced on average $1,000. The FDA's pending decision on semaglutide's shortage status, due April 22nd, is crucial; a favorable ruling could boost HIMS stock significantly.
Charts implemented using Lightweight Charts™